精神分裂症合并物质使用障碍患者锥体外系症状增加。
Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.
作者信息
Potvin S, Pampoulova T, Mancini-Marië A, Lipp O, Bouchard R-H, Stip E
机构信息
Centre de recherche Fernand-Seguin, Hôpital Louis-H Lafontaine, 7331, rue Hochelaga, Montreal, Quebec, Canada H1N 3V2.
出版信息
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):796-8. doi: 10.1136/jnnp.2005.079228.
Abstract
Few data have been gathered about the impact of psychoactive substances on extrapyramidal symptoms (EPS) in schizophrenia, and so far, inconsistent results have been reported. We studied 41 outpatients with schizophrenia (based on DSM-IV criteria), who were divided into two groups: with (n = 17) and without (n = 24) a substance use disorder (alcohol, cannabis, and/or cocaine). Both groups were matched for sociodemographic data and psychiatric symptoms (Positive and Negative Syndrome Scale). EPS were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale, and all patients were stable on either quetiapine or clozapine. Patients receiving anticholinergic drugs were excluded. Analyses of variance were conducted on both groups and showed that schizophrenia patients with a comorbid substance use disorder (especially cocaine) displayed more EPS compared with non-abusing patients.
摘要
关于精神活性物质对精神分裂症锥体外系症状（EPS）的影响，所收集的数据很少，而且迄今为止，报告的结果并不一致。我们研究了41例符合《精神疾病诊断与统计手册》第四版（DSM-IV）标准的精神分裂症门诊患者，他们被分为两组：有物质使用障碍（酒精、大麻和/或可卡因，n = 17）和无物质使用障碍（n = 24）。两组在社会人口统计学数据和精神症状（阳性和阴性症状量表）方面进行了匹配。采用锥体外系症状评定量表和巴恩斯不安腿量表评估EPS，所有患者均稳定服用喹硫平或氯氮平。排除正在接受抗胆碱能药物治疗的患者。对两组进行方差分析，结果显示，与无物质滥用的患者相比，合并物质使用障碍（尤其是可卡因）的精神分裂症患者表现出更多的EPS。
相似文献
1
Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder.精神分裂症合并物质使用障碍患者锥体外系症状增加。
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):796-8. doi: 10.1136/jnnp.2005.079228.
2
Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia.物质滥用者、非物质滥用精神分裂症患者和非物质滥用精神分裂症患者的锥体外系症状。
Mov Disord. 2010 Oct 15;25(13):2188-94. doi: 10.1002/mds.23227.
3
Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.喹硫平用于合并精神分裂症谱系障碍和物质使用障碍患者：一项开放标签试验。
Curr Med Res Opin. 2006 Jul;22(7):1277-85. doi: 10.1185/030079906X112561.
4
Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis.物质滥用与精神分裂症患者锥体外系症状增加有关：一项荟萃分析。
Schizophr Res. 2009 Sep;113(2-3):181-8. doi: 10.1016/j.schres.2009.06.010. Epub 2009 Jul 15.
5
Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.精神分裂症或分裂情感障碍患者伴主要或突出阴性症状者的抗精神病治疗反应。
Schizophr Res. 2012 Feb;134(2-3):195-201. doi: 10.1016/j.schres.2011.09.028. Epub 2011 Oct 21.
6
Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.可溶性白细胞介素-2 受体水平与精神分裂症谱系障碍中喹硫平治疗期间的阳性症状相关。
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1695-8. doi: 10.1016/j.pnpbp.2011.05.011. Epub 2011 May 24.
7
Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.在双相躁狂症患者的对照研究中，喹硫平所致锥体外系症状（EPS）的安慰剂水平发生率。
Bipolar Disord. 2006 Oct;8(5 Pt 1):467-74. doi: 10.1111/j.1399-5618.2006.00350.x.
8
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.CYP2D6基因多态性对长期接受抗精神病药物治疗患者的精神病理症状和锥体外系症状的影响。
J Psychopharmacol. 2006 Nov;20(6):829-33. doi: 10.1177/0269881106062894. Epub 2006 Feb 14.
9
Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis.抗精神病药治疗精神分裂症合并物质使用障碍患者的疗效、可接受性和耐受性：系统评价和荟萃分析。
Eur Neuropsychopharmacol. 2019 Jan;29(1):32-45. doi: 10.1016/j.euroneuro.2018.11.1105. Epub 2018 Nov 22.
10
Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.喹硫平替代抗精神病药物对伴有锥体外系症状的精神分裂症患者症状及生活质量的影响。
Hum Psychopharmacol. 2006 Oct;21(7):439-45. doi: 10.1002/hup.801.
引用本文的文献
1
Association Between Dynapenia/Sarcopenia, Extrapyramidal Symptoms, Negative Symptoms, Body Composition, and Nutritional Status in Patients with Chronic Schizophrenia.慢性精神分裂症患者中肌肉减少症/肌少症、锥体外系症状、阴性症状、身体成分和营养状况之间的关联
Healthcare (Basel). 2024 Dec 30;13(1):48. doi: 10.3390/healthcare13010048.
2
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis.氯氮平治疗对改善精神分裂症谱系障碍患者除尼古丁以外的物质使用障碍的效果：系统评价和荟萃分析。
J Psychopharmacol. 2023 Feb;37(2):135-143. doi: 10.1177/02698811221142575. Epub 2022 Dec 12.
3
Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.部分多巴胺受体激动剂阿立哌唑在成人精神分裂症治疗中的地位：德尔菲共识研究。
BMC Psychiatry. 2022 May 28;22(1):364. doi: 10.1186/s12888-022-04008-9.
4
Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model.慢性可卡因使用者的精神运动症状：一种解释模型。
Int J Environ Res Public Health. 2022 Feb 8;19(3):1897. doi: 10.3390/ijerph19031897.
5
Drug-Induced Movement Disorders and Its Associated Factors Among Patients Attending Treatment at Public Hospitals in Eastern Ethiopia.埃塞俄比亚东部公立医院就诊患者的药物性运动障碍及其相关因素
Neuropsychiatr Dis Treat. 2020 Aug 17;16:1987-1995. doi: 10.2147/NDT.S261272. eCollection 2020.
6
Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis.氟哌啶醇对人体中 δ-9-四氢大麻酚反应的影响：应答者分析。
Psychopharmacology (Berl). 2019 Sep;236(9):2635-2640. doi: 10.1007/s00213-019-05235-x. Epub 2019 Mar 27.
7
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.首发非情感性精神病 493 例急性静坐不能的发生率和危险因素：6 周抗精神病药物随机治疗研究。
Psychopharmacology (Berl). 2017 Sep;234(17):2563-2570. doi: 10.1007/s00213-017-4646-1. Epub 2017 May 31.
8
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia.基因、压力和多巴胺在精神分裂症发病中的作用。
Biol Psychiatry. 2017 Jan 1;81(1):9-20. doi: 10.1016/j.biopsych.2016.07.014. Epub 2016 Aug 6.
9
Predictors of community functioning in schizophrenia and substance use disorder patients.精神分裂症和物质使用障碍患者的社区功能预测因素。
Community Ment Health J. 2013 Jun;49(3):317-22. doi: 10.1007/s10597-012-9525-y. Epub 2012 Jul 31.
10
Evolution of Substance use, Neurological and Psychiatric Symptoms in Schizophrenia and Substance use Disorder Patients: A 12-Week, Pilot, Case-Control Trial with Quetiapine.精神分裂症和物质使用障碍患者物质使用、神经和精神症状的演变：一项使用喹硫平的为期12周的先导性病例对照试验。
Front Psychiatry. 2011 May 13;2:22. doi: 10.3389/fpsyt.2011.00022. eCollection 2011.
本文引用的文献
1
Manual for the Extrapyramidal Symptom Rating Scale (ESRS).锥体外系症状评定量表（ESRS）手册。
Schizophr Res. 2005 Jul 15;76(2-3):247-65. doi: 10.1016/j.schres.2005.02.013. Epub 2005 Apr 18.
2
Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: relationship with cocaine-seeking behavior.可卡因成瘾与纹状体功能亚区中D2受体可用性：与觅药行为的关系。
Neuropsychopharmacology. 2004 Jun;29(6):1190-202. doi: 10.1038/sj.npp.1300420.
3
Quetiapine. A review of its use in the management of schizophrenia.喹硫平。关于其在精神分裂症治疗中应用的综述。
CNS Drugs. 2004;18(3):173-99. doi: 10.2165/00023210-200418030-00004.
4
Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics.使用传统抗精神病药物与非典型抗精神病药物的精神分裂症患者的临床症状与物质使用之间的关系
Am J Drug Alcohol Abuse. 2003 Aug;29(3):553-66. doi: 10.1081/ada-120023458.
5
Chlorpromazine equivalent doses for the newer atypical antipsychotics.新型非典型抗精神病药物的氯丙嗪等效剂量。
J Clin Psychiatry. 2003 Jun;64(6):663-7. doi: 10.4088/jcp.v64n0607.
6
Addiction and the brain: the neurobiology of compulsion and its persistence.成瘾与大脑：强迫行为及其持续性的神经生物学
Nat Rev Neurosci. 2001 Oct;2(10):695-703. doi: 10.1038/35094560.
7
Neurological complications of drug abuse: pathophysiological mechanisms.药物滥用的神经并发症：病理生理机制
Eur J Neurol. 2000 Nov;7(6):595-606. doi: 10.1046/j.1468-1331.2000.00045.x.
8
Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.抗精神病药物从多巴胺D2受体的快速释放：对氯氮平或喹硫平撤药后低受体占有率和早期临床复发的一种解释。
Am J Psychiatry. 1999 Jun;156(6):876-84. doi: 10.1176/ajp.156.6.876.
9
Role of the endogenous cannabinoid system in the regulation of motor activity.
Neurobiol Dis. 1998 Dec;5(6 Pt B):483-501. doi: 10.1006/nbdi.1998.0217.
10
Dual diagnosis: a review of etiological theories.双重诊断：病因学理论综述
Addict Behav. 1998 Nov-Dec;23(6):717-34.
Zotero 插件